Newsroom | MarketersMEDIA Newswire

June 25, 2026

CD Bioparticles Launches Advanced Microneedle Device Customization Services to Accelerate Transdermal Drug Delivery Innovation

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of its comprehensive Microneedle Device Customization Services. This modular platform has integrated cutting-edge micro-fabrication equipment, advanced material engineering, and analytical validation systems to help biotechnology companies and research institutions to seamlessly scale microneedle therapies from bench-top prototypes to clinical-grade pilot production. Microneedles (MNs) are micrometre-scale needles that range in height from 25 to 2,000 micrometres. They are manufactured from a variety of materials and are available in a range of shapes. Microneedle technology is a recent advancement in biomedical science. MN-based drug delivery technology can overcome many of the limitations currently faced in drug delivery, including low absorption rates, low bioavailability, insufficient skin permeability and poor biodistribution. Nanotechnology has significantly transformed microneedle manufacturing processes, shifting from traditional to innovative designs and incorporating various natural and synthetic materials, as well as combinations thereof. Due to its multifaceted and extensive application prospects, microneedle technology has gained widespread popularity in the fields of global biomedical research and drug delivery technology. CD Bioparticles now offers customized microneedle manufacturing equipment and modular production systems to support the entire development process, from early-stage research to pilot-scale production. The company's solutions include laboratory-scale experimental systems (bench-top equipment) for formulation screening and process development, as well as pilot-scale production systems for process validation and small-batch manufacturing. CD Bioparticles' microneedle equipment is built on industrial-grade, high-frequency, impact-jet fluid control technology, and is specifically designed for the precise filling of microneedle tips and coating of substrate materials. The system ensures stable and accurate fluid delivery through the coordinated operation of high-precision core modules. In addition, all components support modularity and flexible customization, including adjustable micro-nozzles and liquid reservoirs of various sizes. The system is fully compatible with a wide range of high-viscosity polymer formulations, including PVP, PVA, HA and PLGA, and is suitable for various microneedle array designs. The custom development process comprises four steps, including 1)requirement evaluation (microneedle product evaluation and manufacturing process analysis); 2) engineering design & system development; 3) equipment manufacturing (machining of core components, automation system integration, software control system integration, and internal mechanical calibration); 4) delivery & technical support (on-site installation and commissioning of microneedle equipment, operator training, and remote technical support for up to one year). CD Bioparticles' microneedle manufacturing systems are widely used for cosmetic microneedle patches, vaccines, exosome delivery systems, peptide delivery platforms, transdermal drug delivery, biologics development, aesthetic skincare products, and medical device manufacturing. CD Bioparticles assists clients in establishing stable, reproducible and scalable microneedle manufacturing platforms to meet their diverse application requirements, from prototype development to pilot production. For more details regarding CD Bioparticles' Microneedle Device Customization Services or to request technical specifications for available micro-fabrication platforms, please visit https://www.cd-bioparticles.net/services/microneedle-device-customization-services.html . About CD Bioparticles CD Bioparticles is an established drug delivery company that provides customized solutions for developing and manufacturing novel biocompatible drug delivery systems. It specializes in various formulation and drug delivery technologies, from conventional liposomes and PEGylated liposomes to polymer microspheres and nanoparticles for drug delivery. The company also provides contract research services for drug delivery formulation, formulation feasibility study, process development and scale-up, as well as analytical and non-clinical research services.

June 25, 2026

Science

STEMart Expands Analytical Equipment Portfolio with Flowmeter Solutions for Bioprocess and Laboratory Applications

STEMart, a US-based provider of comprehensive services for all phases of medical device development, is excited to announce the expansion of its analytical instrumentation portfolio with the launch of its advanced Flowmeter category line. This specialized product expansion can meet the rigorous demands of modern laboratories, pilot plants, and bioprocessing facilities requiring ultra-precise fluid and gas dynamic monitoring. A flowmeter is an instrument used to measure the flow rate of liquids, gases, steam, powders, or mixtures of these substances passing through pipes or conduits. It can measure linear flow, non-linear flow, mass flow, or volumetric flow. The core operating principle determines the basic types of flow meter. Flowmeters fall into two main categories: energy-additive and energy-extractive. Energy additive flowmeters introduce energy into the flowing medium to determine the flow rate, whereas energy-extracting flowmeters extract energy (usually in the form of a pressure drop) from the flowing medium. Common types of flowmeters used in industrial applications include turbine, electromagnetic, positive displacement, pressure-type, variable-area, hydrodynamic, vortex, anemometer, Coriolis, laser Doppler, sonar, optical and ultrasonic. In the research environments, precise flow control is important for accurate results. However, fluctuations in the delivery of gases or liquids can affect cell culture viability, the reproducibility of chromatographic analyses and the outcomes of chemical synthesis directly. To support the research and industrial applications, STEMart has launched flowmeters to address these challenges by offering robust, high-precision instruments to deliver exceptional long-term stability and minimal drift. This new product portfolio features a variety of operating principles to meet specific research and industrial requirements. STEMart, for example, offers the MFE800-S Electromagnetic Flowmeter (CAT#: STEM-AIAE-0553-ZJF), which uses the principle of electromagnetic induction to measure conductive liquids and liquid-solid mixtures. The device requires a conductivity of over 5 μS/cm, making it suitable for a wide range of industrial applications, including the measurement and monitoring of liquid, gas, and steam flow in the industrial and municipal sectors. As there are no obstructions to the flow or moving parts within the measuring tube, this product eliminates additional energy loss and prevents blockages, resulting in significant energy savings. It is particularly well-suited to measuring two-phase liquid-solid flows, such as sewage, slurry, ore slurry, coal slurry and pulp. Furthermore, only the lining and electrodes come into contact with the measured medium. By selecting suitable lining and electrode materials, excellent corrosion and wear resistance can be achieved. Consequently, a wide range of chemical solutions, including strong acids and alkalis, can be measured. For more information regarding technical specifications, bulk ordering, or to view the full product selection, please visit the official STEMart category page at https://www.ste-mart.com/category-flowmeter-1603.htm . About STEMart STEMart is an industry-leading eCommerce platform incorporated with an extensive global footprint and a broad portfolio of more than 10,000 products. It aims to provide better lab materials, medical instruments and consumables, excellent technologies, and high-quality services to global customers in the fields of science, technology, and engineering, from the discovery stage upward to the manufacturing process. STEMart is dedicated to enhancing research and biotech production with simpler and safer protocols to access better health worldwide.

June 22, 2026

Science

Creative Biolabs Empowers Researchers to Overcome Hurdles in Complement Drug Development

Complement-targeted therapeutics have emerged as one of the fastest-growing areas in immunology drug development, with a surge of interest in treatments for autoimmune disorders, kidney diseases, neurological conditions, and rare diseases. However, accurately evaluating complement activation, pathway function, and therapeutic efficacy remains a major challenge for researchers seeking to advance promising drug candidates. Researchers developing complement inhibitors and other complement-targeted therapies often face obstacles such as inconsistent assay performance, limited pathway-specific testing options, and difficulties correlating complement activity with therapeutic outcomes. These challenges can delay candidate selection and increase development costs. To address these needs, Creative Biolabs has expanded its complement testing portfolio, providing researchers with specialized solutions for complement pathway analysis, complement inhibitor screening, and functional evaluation throughout the drug development process. The company's capabilities include: • Complement activation assays for the classical, alternative, and lectin pathways • Complement component analysis, including C1q, C3, C4, and related biomarkers • Complement function assays for therapeutic evaluation • Complement inhibitor screening and pharmacodynamic studies • Customized assay development tailored to specific research objectives Among the featured solutions is the CH50 functional test kit , a hemolysis-based assay designed to quantitatively measure classical complement pathway activity. The kit supports serum and plasma samples from multiple species, providing researchers with a reliable tool for complement function assessment and therapeutic candidate screening. Creative Biolabs also offers hemolysis assay for solutes services to evaluate the hemolytic potential and biocompatibility of compounds, biologics, and formulations. These studies help researchers identify potential safety concerns and better understand complement-mediated cellular responses during preclinical development. "As more organizations invest in complement-targeted therapeutics, the demand for reliable functional assays continues to grow," said a spokesperson from Creative Biolabs. "Our goal is to provide researchers with actionable data that supports candidate selection, mechanism-of-action studies, and preclinical decision-making." Researchers worldwide continue to utilize Creative Biolabs' expertise to accelerate complement research programs. "We needed a reliable CH50 assay to compare multiple complement inhibitors. The assay reproducibility and technical support exceeded our expectations." — Immunology Scientist, U.S. Biotechnology Company "The hemolysis data helped us identify formulation-related safety concerns before advancing to later-stage studies, saving significant development time." — Preclinical Research Director Researchers interested in evaluating complement activation, complement inhibitor efficacy, or hemolytic activity can consult with Creative Biolabs specialists to discuss project-specific testing strategies. To learn more, please visit https://www.creative-biolabs.com/complement-therapeutics/ . About Creative Biolabs Creative Biolabs is a biotechnology company with a strong focus on complement therapeutic research, offering specialized platforms and services that accelerate the discovery, characterization, and optimization of complement‑targeted drugs. The company provides integrated solutions spanning complement pathway analysis, inhibitor development, functional assays, and translational studies, enabling researchers to explore mechanisms of complement activation and advance next‑generation complement‑based therapeutics.

June 18, 2026

Science

Consumer Demand for Product Transparency Continues to Grow Across the Botanical Products Industry

As consumers become increasingly informed about the products they purchase, transparency has emerged as one of the most important factors influencing buying decisions across the botanical, supplement, and wellness industries. Today's consumers have greater access to information than ever before and are increasingly seeking detailed product information before making a purchase. From ingredient sourcing and manufacturing standards to independent laboratory testing and product verification, transparency is becoming a key trust signal for brands operating in competitive consumer markets. Super Speciosa , a U.S.-based botanical products company, believes this shift reflects a broader movement toward accountability and informed decision-making among consumers. "Consumers today expect more than marketing claims. They want access to information they can review and verify for themselves," said Super Speciosa. "Transparency helps build trust and allows consumers to make purchasing decisions with greater confidence." Super Speciosa provides consumers with access to batch-specific laboratory reports through a comprehensive product traceability system. Every product is assigned a unique batch number and includes a QR code that allows customers to quickly access the corresponding laboratory results for the exact batch they purchased. This approach provides a level of transparency and verification that remains uncommon across much of the broader supplement and botanical products marketplace. As demand for transparency continues to grow, many consumers are placing increased value on third-party testing and product-specific verification systems that provide insight into product quality and consistency. To help meet these expectations, Super Speciosa provides access to batch-specific laboratory testing information for products distributed through its website. Testing is conducted by independent third-party laboratories accredited to the ISO/IEC 17025 standard, a globally recognized benchmark for laboratory competence and quality assurance. By making this information available to consumers, Super Speciosa enables customers to review detailed testing data associated with individual product batches. As consumer expectations continue to evolve, Super Speciosa believes transparency must be supported by rigorous quality standards. Every batch undergoes a comprehensive testing panel conducted by independent third-party laboratories, including screening for microbial contaminants such as Salmonella and harmful bacteria, heavy metals, mold, and verification of multiple naturally occurring alkaloids. The company follows National Sanitation Foundation (NSF) standards for dietary supplements and maintains a strict quality assurance process in which any batch that does not meet established standards is discarded and never offered for sale. Industry observers note that transparency initiatives are becoming more common as consumers seek greater visibility into the products they purchase and the standards behind them. Brands that invest in verification systems and independent testing may be better positioned to meet evolving consumer expectations. "Transparency is no longer viewed as a competitive advantage by many consumers—it is increasingly becoming an expectation," Super Speciosa added. "The companies that prioritize accessibility, accountability, and verification are helping shape the future of the industry." As consumer awareness continues to grow, Super Speciosa expects demand for independent testing, product traceability, and quality verification to remain important factors influencing purchasing decisions throughout the botanical products sector. For more information, visit https://superspeciosa.com/ Super Speciosa is a U.S.-based botanical products company committed to transparency, quality, and consumer education. Through third-party laboratory testing and product verification initiatives, the company works to provide consumers with greater access to information about the products they purchase. Contact Information: Super Speciosa 7901 4th St N Ste 300 St. Petersburg, FL 33702 United States Email: ss@superspeciosa.com Website: https://superspeciosa.com/

June 16, 2026

Science

Inzecto Announces Newly Granted Upgraded EPA Registration Providing Three Months of Continuous Mosquito Control

INZECTO , a developer of Pest Management technologies, announces that the United States Environmental Protection Agency (EPA) has granted an upgraded label registration for the company’s proprietary mosquito trap. This updated regulatory milestone extends the recognized duration of continuous insect control from 35 days to a period of three months. The regulatory upgrade allows public and private pest management entities to implement year-round mosquito management options with quarterly services. Essentially, this device now simplifies the challenges associated with mosquito and mosquito-borne disease management. “This concludes a long and meticulous scientific evaluation process with federal regulators,” states Enrico Levi, founder and CEO of INZECTO. “This newly updated registration validates the duration of the technology using rigorous testing protocols in the US as well as internationally.” Enrico Levi Another major modification on the revised label is the removal of the Personal Protective Equipment (PPE) usually listed on product labels, due to the innovative design of the device. According to Levi, “Standard commercial mosquito control applications and vector mitigation protocols (including spraying, fogging, as well as other mosquito traps) typically require users to utilize specific safeguards, including long sleeves, protective gloves, and respirators certified by NIOSH. Under the revised federal registration, given the structural safety of the INZECTO Mosquito Trap, operators can handle and deploy the device without PPE. This operational simplicity offers relief for Professional Pest Management personnel who frequently provide applications when summer temperatures can be excessively hot.” The device uses a geometric, pyramid‑style structure designed to contain water, maintain high internal humidity, and slow evaporation. This creates a stable microenvironment that is appealing to egg-laying female mosquitoes looking for places to rest and deposit eggs. Levi notes that its patented design draws on research about how mosquitoes respond to humidity, surface texture, and protection from air movement, rather than relying on a single factor of attractiveness. Only the interior surface of the trap is covered with a microporous coating that releases micro-doses of adulticide and larvicide over time. Users of the INZECTO trap do not contact any active ingredients, therefore do not need PPE for safety and protection. The exposure of mosquitoes to both adulticide and larvicide affects multiple points in the mosquito life-cycle, especially limiting the development of larvae within the device for three months. Such a combined action of adulticide and larvicide simultaneously prevents the development of resistance that often arises from repetitive use of a single insecticide class. The overall concept is to utilize an ‘Attract-and-Kill Strategy’ by providing the most attractive breeding site for mosquitoes, which reduces oviposition in other water- holding containers. “Our design utilizes mosquito behavior to manage populations effectively for three months,” explains Levi, “Female mosquitoes naturally select localized, humid environments to deposit eggs and rest, which makes the microclimate inside the trap highly competitive against alternative yard containers.” This three-month EPA-validated efficacy in mosquito control supports a proactive, quarterly deployment schedule rather than conventional reactive treatments. Traditional Pest Control frequently initiates applications after localized insect populations have reached peak density. A systematic four-times-a-year maintenance cycle allows public health agencies and property managers to lower mosquito populations year-round. Late autumn deployments, specifically from October to December, assist in suppressing the mosquitoes that would emerge during the following spring. This updated availability arrives amid expanding geographic ranges for vector species, influenced by shifting global climate patterns and prolonged summer seasons. Regulatory trends have simultaneously restricted the allowable volume and residual duration of traditional chemical barrier treatments. The simplicity, efficacy, duration, and mode of action of the trap allow either a stand-alone application or integration with fogging, spraying, or other forms of mosquito control. Ultimately, this new EPA registration of the INZECTO Mosquito Trap confirms the company’s commitment to combining knowledge of insect biology with innovative technology in order to provide effective and long-lasting public health tools with no hazard to humans or the environment.

May 28, 2026

Science

Biointron Launches RushMab as Antibody Production Market Targets $39.8B by 2033

Grand View Research puts the global antibody production market at USD 15.44 billion for 2024, with projections of USD 39.80 billion by 2033, an 11.2 percent compound annual growth rate tied directly to the expansion of biologic drug pipelines and the rising volume of pre-clinical validation work being outsourced to specialist CROs. Biointron Biological Inc., a contract research organization based in Cambridge, Massachusetts, has launched Small-Scale Antibody Expression Packages under the RushMab™ brand, compressing antibody delivery timelines to as few as 10 days for purified, quality-controlled material. Pharma and biotech companies are outsourcing more pre-clinical work than ever before. The antibody contract manufacturing segment alone represented USD 34.72 billion in addressable opportunity as of 2026, per a market report published in April of that year via GlobeNewswire. Speed is now the primary variable. When expression turnaround runs long, candidate screening cycles slip with it, sometimes by weeks, and for research-stage companies working under tight capital constraints, those delays carry real cost. The shift has made fast, small-batch CRO capability a procurement priority rather than a convenience. For more information, visit https://www.biointron.com/antibody-production/rushmab-small-scale-expression-packages.html Recombinant antibody expression converts a sequence file into a functional protein a research team can actually use. Biointron's RushMab™ line covers that process at four delivery speeds. Teams that only need plasmid material can get 100 micrograms of transfection-grade expression plasmids from the RushMab™-Gene package in four days. RushMab™ Super adds purification and delivers antibody with titer detection in eight. Both Mini and Standard packages hit the 10-day mark with full purification: the Mini at a minimum of 100 micrograms, the Standard at over 1 milligram, with endotoxin testing below 1 EU/mg and SDS-PAGE plus SEC-HPLC verification on both. IgG, Fab, VHH, and ScFv formats are all supported, covering the structural range most common in early biologic research. Service details are on Biointron's Small-Scale Antibody Expression Packages page. Speed-to-delivery has become the main competitive axis in small-scale antibody expression. GenScript Biotech Corporation, listed on the Hong Kong Stock Exchange, runs a TurboCHO™ transient expression platform that publishes five-business-day turnaround for select configurations. Sino Biological cites a 10-day gene-to-antibody standard across its high-throughput recombinant service. Biointron competes at that same benchmark with the added breadth of IgG, Fab, VHH, and ScFv support in one service menu. ISO 9001:2015 certification and membership in MassBio – the Massachusetts life sciences industry association – round out the compliance profile that pharmaceutical procurement teams typically require. "As biologic pipelines grow and AI-driven candidate generation accelerates, the wet-lab expression step has become the rate-limiting factor in early research programs," said Mia Deng of Biointron Biological Inc. She noted that RushMab™ was built to keep pace with how fast modern discovery workflows now move. "A 10-day turnaround for a fully purified, endotoxin-tested antibody removes a friction point that used to cost teams weeks between candidate iterations." Biointron was founded in 2012. Since then it has delivered recombinant antibody services to more than 2,500 biotech and pharmaceutical organizations spanning more than 20 countries. In 2025, Scientist.com recognized the company with its Supplier Performance Recognition Award for drug discovery research services. Cambridge, Massachusetts, puts Biointron inside one of North America's most concentrated corridors for biologic research, academic medical centers, pharmaceutical research units, and venture-backed startups, all operating within close proximity and generating consistent demand for fast, reliable CRO output. The full range of Antibody Expression Packages is available on the company's website. About Biointron Biological Inc. Biointron Biological Inc . is a Cambridge, Massachusetts-based contract research organization specializing in antibody discovery, antibody production, stable cell line development, and protein expression services for biotech and pharmaceutical clients worldwide. Founded in 2012 and ISO 9001:2015 certified, Biointron has served more than 2,500 organizations across more than 20 countries.

May 28, 2026

Science

Biointron Launches RushMab Packages to Deliver Purified Antibodies in 10 Days

Antibody production timelines have long been one of the most stubborn bottlenecks in early-stage drug discovery. Researchers who need recombinant proteins for feasibility testing, candidate screening, or assay development have typically waited weeks for material to arrive, time that compounds across every iteration of a research program. Biointron Biological USA Inc . (“Biointron”), a contract research organization specializing in antibody discovery and production services with offices located in Cambridge, Massachusetts, and Piscataway, New Jersey, has released Small-Scale Antibody Expression Packages under the RushMab™ brand, compressing the wait to as few as 4 days for transfection-grade expression plasmids, and 10 days for purified, quality-controlled antibody material. Beyond shortened turnaround time, RushMab™ is designed to support high-throughput antibody expression workflows. This platform can process up to thousands of samples within a single batch, allowing researchers to express, purify, and compare large panels of antibody candidates in parallel. This capability is particularly relevant for early-stage antibody discovery, where rapid candidate prioritization often depends not only on how quickly material can be produced, but also on how many variants can be evaluated side by side. The timing reflects sustained pressure across the biopharmaceutical sector to accelerate pre-clinical workflows. According to Grand View Research, the global antibody production market was valued at approximately USD 15.44 billion in 2024 and is projected to reach USD 39.80 billion by 2033, expanding at a compound annual growth rate of 11.2 percent. For more information, please visit https://www.biointron.com/antibody-production/rushmab-small-scale-expression-packages.html That growth is driven in part by rising demand for rapid, small-batch antibody material to support the growing volume of biologic drug candidates entering early research pipelines. As AI-assisted antibody design tools generate candidate sequences faster than wet-lab validation can keep pace, the pressure on expression turnaround has intensified further. Recombinant antibody expression is the process by which a defined antibody sequence provided as a gene construct or sequence file, is introduced into a host cell system, typically mammalian, to produce functional antibody protein that can be harvested, purified, and used in downstream research. Biointron’s RushMab™ packages are built around this workflow, with four tiers designed to match different research needs: The RushMab™-Gene package delivers 100 micrograms of transfection-grade expression plasmids within four days. The RushMab™-Super package offers purified antibody with titer detection in eight days. The RushMab™-Mini package provides no fewer than 100 micrograms of purified antibody alongside expression plasmids within 10 days, verified by SDS-PAGE and SEC-HPLC analysis. The RushMab™-Standard package delivers more than one milligram of purified antibody with endotoxin levels below 1 EU/mg within the same 10-day window, backed by full SDS-PAGE and SEC-HPLC quality documentation. Speed and throughput have become defining competitive factors in small-scale antibody expression. In early discovery programs, researchers often need to evaluate dozens, hundreds, or even thousands of antibody candidates before selecting leads for deeper characterization. RushMab™ addresses this need by combining fast production timelines with high-throughput batch processing, enabling large candidate panels to be generated and compared in parallel. Biointron’s RushMab™ packages position the company within this competitive tier while extending format flexibility to IgG, Fab, VHH, and ScFv sequences, antibody types that are each suited to distinct research applications and that not all rapid-expression providers accommodate across a single service menu. Researchers today are working faster than ever, and waiting weeks for a small antibody batch can stall an entire program. RushMab™ was built specifically to close that gap. Whether a team needs plasmid-only output in four days or a fully purified, endotoxin-tested antibody in ten, we now have a structured option for each stage of that decision. Biointron was founded in 2012 and has since delivered recombinant antibody services to more than 3,000 biotech and pharmaceutical organizations across more than 20 countries. The company is a member of various life sciences industry associations, such as MassBio (Massachusetts), BioNJ (New Jersey), California Life Sciences, and the UK BioIndustry Association (BIA). Biointron also holds ISO 9001:2015 certification. Its Cambridge, Massachusetts address places it within one of North America’s most active clusters for biologic drug development, where proximity to academic medical centers and pharmaceutical research groups has historically driven demand for responsive CRO services. Biointron received the 2025 Scientist.com Supplier Performance Recognition Award for outstanding delivery of drug discovery research services. The RushMab™ packages are available now through Biointron’s Small-Scale Antibody Expression Packages service page. About Biointron Biointron is a Shanghai-based antibody contract research organization with offices in Cambridge, MA and Piscataway, NJ, specializing in antibody discovery, antibody production, stable cell line development, and protein expression services for biotech and pharmaceutical clients worldwide. Founded in 2012 and ISO 9001:2015 certified, Biointron has served more than 3,000 organizations across 20+ countries.

May 28, 2026

Science

Energy Crunch Spurs Ever Wonder Adventure To Advance Waste-To-Power Action Today

Energy Crunch Spurs Ever Wonder Adventure To Advance Waste-To-Power Action Today Ever Wonder Adventure has expanded its climate awareness work as countries respond to an ongoing energy crunch caused by fossil fuel supply pressure, transportation disruption, and rising fuel import costs. The organization’s latest environmental message connects energy security, food waste reduction, renewable energy, and conservation into one urgent public issue: protecting natural wonders while reducing dependence on unstable fossil fuel systems. Non-oil producing countries have been placed under particular pressure as global fuel supply chains remain vulnerable to shipping delays, geopolitical instability, refinery limitations, and transportation cost increases. These pressures can raise electricity prices, affect food distribution, strain local economies, and reduce funding available for conservation programs. That pressure is creating new urgency around local renewable energy sources. Ever Wonder Adventure is highlighting anaerobic fermentation, also known as anaerobic digestion, as one practical solution. The process uses microorganisms to break down organic waste in oxygen-free environments. That process produces biogas, which can be used for electricity, heating, cooking fuel, or upgraded renewable natural gas. Food waste has become one of the most overlooked climate challenges. When discarded food decomposes in landfills, it releases methane, a powerful greenhouse gas linked to climate change. Food waste is increasingly being discussed as one of the largest preventable sources of carbonization and climate pollution. The same discarded material can also become an energy resource when captured and processed through controlled anaerobic fermentation systems. This makes food waste reduction a climate strategy, a renewable energy strategy, and a waste management strategy at the same time. Ever Wonder Adventure is connecting this technology to a broader call for environmental guardianship. The organization’s conservation work focuses on protecting untouched natural wonders, including serene coastlines, picturesque hills, rural villages, wildlife habitats, and fragile ecosystems. These places are increasingly exposed to the effects of climate change, including extreme weather, biodiversity loss, soil degradation, rising temperatures, and damage to local tourism economies. Ever Wonder Adventure states that the worsening climate crisis is no longer a distant environmental concern. It is affecting the places that communities value, the landscapes that travelers seek, and the ecosystems that support long-term life on Earth. Further information about the organization’s conservation support work is available at https://everwonderadventure.com/support-us . The organization also provides additional environmental information at https://everwonderadventure.com/saving-earth , where its campaign for saving Earth and protecting Mother Nature is outlined. The central message is immediate: food waste can no longer be treated only as garbage. For countries facing fossil fuel insecurity, food waste can become part of a domestic energy solution. For communities facing climate disruption, waste-to-energy systems can reduce emissions. For conservation groups, these solutions can help protect the natural landscapes already under pressure from global warming. Ever Wonder Adventure’s campaign frames renewable energy adoption, food waste transformation, and nature protection as urgent steps in the same fight. The organization is using its platform to encourage practical climate awareness at a time when energy costs, environmental damage, and carbon emissions are all demanding faster action.

May 28, 2026

Science

Creative Biolabs Launches Integrated Analytical Platform to Optimize Biomass and Biogas Fermentation

As global demand for renewable energy, sustainable bioprocessing, and industrial biotechnology continues to rise, Creative Biolabs has expanded its quantitative profiling solutions for biomass analysis , algae characterization, and biogas fermentation monitoring. The advanced analytical platform is designed to help researchers and biotechnology companies achieve accurate biomass characterization, optimize fermentation efficiency, and accelerate bioenergy development through high-quality quantitative data. Accurate quantitative characterization remains a major challenge in biomass utilization and industrial fermentation optimization due to the complexity and variability of biological materials. To address these analytical bottlenecks, Creative Biolabs provides integrated profiling workflows combining chromatography, mass spectrometry, and customized data analysis strategies. Key features of the platform include: • Quantitative profiling of biomass components, including carbohydrates, lipids, proteins, lignin, metabolites, and fermentation-related compounds • Algae multi-component quantitative analysis supporting biofuel, nutraceutical, and environmental biotechnology research • Biogas fermentation process-based quantitative profiling for anaerobic digestion monitoring and methane production optimization • High-sensitivity analytical workflows for complex biological and industrial samples • Flexible project customization for renewable energy, industrial biotechnology, microbial fermentation, and carbon utilization studies As biomass-derived resources and algae-based production systems continue to gain importance in sustainable manufacturing and clean energy innovation, researchers increasingly require reliable analytical solutions for feedstock evaluation, process monitoring, and quality assessment. "Scaling up bioenergy production has long been hindered by the unpredictable nature of biological feedstocks," said the Chief Scientist at Creative Biolabs. "Our expanded testing platform injects molecular-level clarity into the process, effectively removing the guesswork for refiners and biotechnologists striving toward a net-zero future." The solutions are suitable for applications including: • Biomass feedstock characterization • Anaerobic digestion and biogas research • Fermentation process optimization • Renewable bioenergy development • Algae metabolite analysis • Industrial microbial biotechnology • Environmental and carbon utilization research Frequently Asked Questions (FAQs) Q1: What specific challenges does Creative Biolabs’ profiling platform address? The platform overcomes the analytical limitations of complex biological matrices, allowing researchers to accurately quantify highly variable compounds in raw biomass, microalgae cultures, and active biogas fermenters without sample cross-interference. Q2: What analytical technologies are used in the profiling workflows? Creative Biolabs utilizes advanced analytical technologies including chromatography, mass spectrometry, and customized bioanalytical workflows to achieve sensitive and reliable quantitative analysis. Q3: Can the services be customized for specific industrial biotechnology projects? Yes. Creative Biolabs provides flexible, client-specific protocols tailored to unique sample types, target analytes, and volume requirements across the renewable energy and microbial fermentation sectors. Researchers and biotech companies interested in biomass characterization, algae profiling, or fermentation analytics can explore customized solutions at https://www.creative-biolabs.com/glycoprotein/biomass-components-quantitative-profiling-services.htm . About Creative Biolabs Creative Biolabs provides advanced analytical and customized research services for biomass characterization, algae component analysis, and biogas fermentation. With expertise in chromatography, mass spectrometry, and bioanalytical technologies, the company supports global partners in renewable bioenergy, industrial biotechnology, fermentation optimization, and sustainable bioprocess development.

May 27, 2026

Science

Creative Biolabs Launches Integrated iPSC Reprogramming and Alzheimer's Disease Cell Model Platform

As the complexity of the human brain continues to challenge traditional research models, scientists are increasingly turning to human iPSC-derived neuronal systems to obtain more predictive and translational data. Conventional animal models often fail to fully replicate the molecular and cellular mechanisms involved in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Creative Biolabs addresses this challenge by offering human iPSC-based disease models that closely mimic patient-specific neurological pathology and cellular behavior. "Our integrated stem cell platform enables researchers to generate highly characterized neuronal cell types and disease-specific models with improved reproducibility and physiological relevance," said a senior scientist at Creative Biolabs. "We aim to support global neuroscience researchers in accelerating therapeutic discovery for Alzheimer's disease and other neurodegenerative disorders." iPSC Reprogramming Services Creative Biolabs provides comprehensive iPSC reprogramming services using multiple non-integrating technologies, including: Episomal vector-based reprogramming Sendai virus reprogramming mRNA-based reprogramming methods These approaches help maintain genomic stability while minimizing integration-associated risks, making the generated iPSC lines ideally suitable for downstream disease modeling, regenerative medicine research, and drug screening applications. The company supports reprogramming from a wide range of somatic cell sources and offers extensive pluripotency characterization and quality control analysis. Specialized Neuronal Differentiation Capabilities Creative Biolabs provides specialized neuronal differentiation services capable of generating high‑purity neural cell populations tailored to research needs. These include dopaminergic, GABAergic, and glutamatergic neurons, as well as motor and sensory neurons, astrocytes, and microglia. The resulting human iPSC‑derived neural cells are optimized for a wide range of applications, such as neurodegenerative disease modeling, high‑throughput drug screening, neurotoxicity assessment, biomarker discovery, and mechanistic studies. A key highlight of the expanded platform is the development of advanced Alzheimer's disease iPSC models . Using CRISPR/Cas9 genome editing, Creative Biolabs introduces clinically relevant mutations—such as those in APP, PSEN1, and PSEN2—to recapitulate hallmark AD pathologies. These engineered models enable in‑depth investigation of amyloid‑beta accumulation, tau hyperphosphorylation, synaptic dysfunction, and neuroinflammatory processes. The models are suitable for both basic neuroscience research and preclinical therapeutic evaluation, helping pharmaceutical and biotechnology companies improve target validation and candidate screening efficiency. Supporting Global Drug Discovery and Translational Medicine By integrating stem cell reprogramming, neuronal differentiation, and disease-specific engineering into a single workflow, Creative Biolabs simplifies complex neuroscience research processes and reduces technical barriers for research teams worldwide. Researchers interested in accelerating Alzheimer's disease and neurodegenerative disease drug discovery can explore Creative Biolabs' iPSC reprogramming services, neuronal differentiation platform, and customized disease models for translational neuroscience applications. To learn more or to request custom iPSC disease models, please visit https://www.creative-biolabs.com/stem-cell-therapy/ . About Creative Biolabs Creative Biolabs is a global biotechnology company providing advanced stem cell technologies, disease modeling services, and custom research solutions for regenerative medicine, neuroscience, and drug discovery.

May 27, 2026

Science

Creative Diagnostics Expands Preclinical CRO Services with Advanced MERS-CoV Animal Models to Accelerate Coronavirus Vaccine and Drug Development

As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the expansion of its preclinical portfolio with the launch of its specialized MERS-CoV Animal Model services. Designed to meet the critical global demand for effective Middle East Respiratory Syndrome Coronavirus (MERS-CoV) research, these models bridge the gap between in vitro discovery and clinical evaluation, providing a robust platform for testing novel vaccine candidates and antiviral therapies. MERS-CoV is an emerging zoonotic virus that is considered to be one of the major public health threats. Since 2012, there have been consistent monthly cases of MERS-CoV causing severe respiratory illness, resulting in the death of approximately 35% of confirmed patients. It is believed that the virus is transmitted from camels in Middle Eastern countries through contact between humans and animals. The viral genome structure provides crucial insights into its pathogenicity and associated virulence factors. However, recent studies indicate that our understanding of the development of novel therapeutic strategies aimed at inducing antiviral immunity remains limited. The severity of MERS-CoV infection underscores the urgent need for effective therapeutic approaches. The ongoing threat to global public health posed by MERS-CoV, coupled with the need for novel therapeutic strategies, has driven the development of animal models that can reliably reproduce MERS-CoV-associated pathology in human infections. With extensive expertise and cutting-edge resources, Creative Diagnostics is committed to providing reliable animal models for MERS-CoV infection. This enables clients worldwide to gain a deeper understanding of the virus's complex mechanisms. Backed by a dedication to scientific excellence, these models show great promise in advancing research into the intricate pathogenesis of MERS-CoV, assessing potential therapeutic interventions and accelerating the development of effective strategies to combat this potent virus. Creative Diagnostics' MERS-CoV animal models primarily include the MERS-CoV Virus Tracheal Intubation Infection Rhesus Monkey Model, and the MERS-CoV Virus Intranasal Infection Mouse Model. By addressing key conditions such as mortality rates associated with severe respiratory disease, the absence of neurological complications at high viral loads and sustained high levels of viral replication in the lungs, Creative Diagnostics' animal models simulate human infection with MERS-CoV. They retain the innate expression of the MERS-CoV host receptor DPP4 and feature genetically modifiable host genes, making them suitable for vaccine and therapeutic response studies. Creative Diagnostics' animal models provide researchers with a controlled experimental platform on which to study viral behaviour, transmission, immune responses, and potential therapeutic approaches. Creative Diagnostics also offers a range of services to support MERS-CoV animal model research, including pathological analysis, immune response profiling, vaccine and antiviral compound efficacy testing, and data analysis and interpretation. Creative Diagnostics will be showcasing these preclinical services, alongside their comprehensive suite of viral and bacterial infection models, at the upcoming ASM Microbe 2026 conference in Washington, D.C., from June 4-7, at booth #1608. Attendees are invited to meet with their scientific team to discuss custom study designs and partnership opportunities. For more information about the MERS-CoV Animal Model services or to request a consultation, please visit https://antiviral.creative-diagnostics.com/mers-cov-animal-model.html . About Creative Diagnostics Headquartered in New York, Creative Diagnostics is a consulting and experimental service provider specializing in virology and microbiology. The company provides comprehensive solutions to conquer obstacles in virology and microbiology research, from high-security infrastructure provision, biosafety regulation elucidation, to expert viral system assistance.

Science News

Creative Biolabs Accelerates CRISPR Research with Integrated Gene Editing Solutions

Colorado Wildfire & Disaster Preparedness Book With Real Examples Released

Food Waste To Energy Gains Urgency As London Faces Extreme Heat

Creative Diagnostics Launches Tritosome Reagents to Advance In Vitro Characterization of ADCs and Oligonucleotide Therapeutics

CD Bioparticles Launches Advanced Microneedle Device Customization Services to Accelerate Transdermal Drug Delivery Innovation

STEMart Expands Analytical Equipment Portfolio with Flowmeter Solutions for Bioprocess and Laboratory Applications

Creative Biolabs Empowers Researchers to Overcome Hurdles in Complement Drug Development

Consumer Demand for Product Transparency Continues to Grow Across the Botanical Products Industry

Inzecto Announces Newly Granted Upgraded EPA Registration Providing Three Months of Continuous Mosquito Control

Biointron Launches RushMab as Antibody Production Market Targets $39.8B by 2033

Biointron Launches RushMab Packages to Deliver Purified Antibodies in 10 Days

Energy Crunch Spurs Ever Wonder Adventure To Advance Waste-To-Power Action Today

Creative Biolabs Launches Integrated Analytical Platform to Optimize Biomass and Biogas Fermentation

Creative Biolabs Launches Integrated iPSC Reprogramming and Alzheimer's Disease Cell Model Platform

Creative Diagnostics Expands Preclinical CRO Services with Advanced MERS-CoV Animal Models to Accelerate Coronavirus Vaccine and Drug Development

ALL NEWS